companydata.dkcompanydata.dk

Y-mAbs Therapeutics A/S: Financial statements 2025

CVR: 37053678

Source: annual report 2025, Danish Business Authority

01/01/2025 – 31/12/2025

Y-mAbs Therapeutics A/S (CVR 37053678) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK 29,300,371 and a net result of DKK -38,461,598 compared with DKK -12,500,464 the year before. That is a decrease of 60.5% compared with the year before. Equity in the 2025 report amounted to DKK -163,651,844. The company had 53 employees in the financial year.

Gross Profit
DKK 29,300,371
Profit/Loss
DKK -38,461,598
Equity
DKK -163,651,844
Total Assets
DKK 15,043,147
Employees
53

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2025-29.3M-38.5M-163.7M53
2024-74.3M-12.5M-125.2M56
2023-70.7M-27.7M-112.7M59
2022-82.3M-85.7M-84.9M101
2021-67.5M-42.1M-39.3M88

Official annual report

View the official annual report directly on the page with a Pro subscription.

How creditworthy is Y-mAbs Therapeutics A/S?

See the CDS score and get a full credit report with recommended credit limit and payment terms.

Read about the CDS score

Events in 2025

Y-mAbs Therapeutics A/S appoints new auditorDec 29, 2025

As of December 29, 2025, EY Godkendt Revisionspartnerselskab has been appointed auditor of Y-mAbs Therapeutics A/S.

Auditor steps down at Y-mAbs Therapeutics A/SDec 29, 2025

As of December 29, 2025, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of Y-mAbs Therapeutics A/S.

Antoine Bernasconi joins the board of Y-mAbs Therapeutics A/SSep 29, 2025

As of September 29, 2025, Antoine Bernasconi has joined the board of directors of Y-mAbs Therapeutics A/S.

Vincent Sainte-Catherine joins the board of Y-mAbs Therapeutics A/SSep 29, 2025

As of September 29, 2025, Vincent Sainte-Catherine has joined the board of directors of Y-mAbs Therapeutics A/S.

Julien Forest joins the board of Y-mAbs Therapeutics A/SSep 29, 2025

As of September 29, 2025, Julien Forest has joined the board of directors of Y-mAbs Therapeutics A/S.

Johan Ernst Wedell-Wedellsborg leaves the board of Y-mAbs Therapeutics A/SSep 29, 2025

As of September 29, 2025, Johan Ernst Wedell-Wedellsborg has left the board of directors of Y-mAbs Therapeutics A/S.

Thomas Gad leaves the board of Y-mAbs Therapeutics A/SSep 29, 2025

As of September 29, 2025, Thomas Gad has left the board of directors of Y-mAbs Therapeutics A/S.

Michael Joseph Rossi leaves the board of Y-mAbs Therapeutics A/SSep 29, 2025

As of September 29, 2025, Michael Joseph Rossi has left the board of directors of Y-mAbs Therapeutics A/S.

Peter Paul Pfreundschuh leaves the board of Y-mAbs Therapeutics A/SSep 29, 2025

As of September 29, 2025, Peter Paul Pfreundschuh has left the board of directors of Y-mAbs Therapeutics A/S.

Vincent Sainte-Catherine joins Y-mAbs Therapeutics A/S as adm. dir.Sep 29, 2025

As of September 29, 2025, Vincent Sainte-Catherine is registered as adm. dir. of Y-mAbs Therapeutics A/S.

About Y-mAbs Therapeutics A/S

Y-mAbs Therapeutics A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2015. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Vincent Sainte-Catherine. The board consists of Antoine Bernasconi (chair), Julien Forest and Vincent Sainte-Catherine. The company is owned by Y-mAbs Therapeutics, Inc.. The company has 13 employees (2026). In 2025, the company reported a gross profit of DKK 29,300,371 and a net result of DKK -38,461,598 compared with DKK -12,500,464 the year before. Equity in the 2025 report amounted to DKK -163,651,844.

Source: annual report 2025, Danish Business Authority